Today: 20 March 2026
RELX share price rises in London after buyback update as investors eye Feb. 12 results
7 January 2026
1 min read

RELX share price rises in London after buyback update as investors eye Feb. 12 results

London, Jan 7, 2026, 08:48 GMT — Regular session

Shares in RELX (REL.L) rose 0.8% to 3,103 pence in early London trade on Wednesday after the company disclosed another round of share repurchases. The stock ranged between 3,089 and 3,117 pence and remains about a quarter below its 52-week high of 4,205 pence. Google

The steady drumbeat of buybacks has given traders a near-term anchor as they look past day-to-day swings and toward the next set of company numbers. RELX has been a defensive holding for many UK investors, prized for subscription-style revenue from legal, risk and scientific information services.

The broader FTSE 100 fell 0.5% to 10,074 in early trade, a day after closing at a record 10,123. RELX was among the names holding up better than the blue-chip index in the opening hour. Google

RELX said it bought 313,411 shares on Jan. 6 at an average price of 3,063.9622 pence, with prices ranging from 3,037 to 3,086 pence. The group said it has bought 959,364 shares since Jan. 2 and now holds 5,067,236 shares in treasury. Investegate

The stock had already found support earlier in the week, rising 3.6% on Monday to 30.90 pounds, outperforming the wider market. Trading volume was 2.2 million shares, well below its 50-day average of about 5.1 million, MarketWatch data showed. MarketWatch

Buybacks shrink the share count and can lift earnings per share, a common profit-per-share yardstick. They can also signal that management prefers returning cash to shareholders rather than piling it up on the balance sheet.

But buybacks will not settle the bigger question for investors: whether RELX can sustain growth and pricing power as customers scrutinise budgets. Any disappointment on margins or renewals would likely outweigh day-to-day support from repurchases.

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Unilever shares slip in early London trade — what investors watch before Feb 12 results
Previous Story

Unilever shares slip in early London trade — what investors watch before Feb 12 results

Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus
Next Story

Haleon PLC stock edges lower after executive share-deal filing, with earnings in focus

Go toTop